Skip to content
CancerIndex

Publication

Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience.

Manuel Weber, Leah Trumet, Fabienne Lange, Julia Murk, Philipp Schubert, Hasan Alsamra, Joy Backhaus, Stefanie Corradini, Marco Kesting, Sarina Müller, Joan Morris, Marlen Haderlein

Cancer immunology, immunotherapy : CIISep 4, 2026PMID 42709195doi:10.1007/s00262-026-04515-8 PMC13554004Journal ArticleClinical Trial, Phase IIRandomized Controlled TrialMulticenter StudypubmedProvenance
Source
PubMed
Retrieved
Sep 26, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260926-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

PURPOSE: Combination immunotherapy has shown encouraging activity across multiple solid tumors. We report the complete and consecutive cohort of patients with locally advanced oral squamous cell carcinoma (OSCC) treated at a single center within the prospective, multicenter, randomized phase 2…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.